Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Open-label Extension Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

Phase 3

Recruiting

Conditions: Hypercholesterolemia

Interventions: Drug: Enlicitide Decanoate

First Posted Date: 2024-07-09

Last Posted Date: 2025-05-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 3000

Registration Number: NCT06492291

Locations: 🇮🇱
Rambam Health Care Campus ( Site 1742), Haifa, Israel
🇺🇸
Alliance for Multispecialty Research, LLC ( Site 0027), Daphne, Alabama, United States
🇺🇸
G&L Research ( Site 0035), Foley, Alabama, United States

and more 219 locations

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Phase 1

Recruiting

Conditions: Metastatic Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma

Interventions: Biological: Sacituzumab tirumotecan
Biological: Enfortumab Vedotin
Biological: Pembrolizumab

First Posted Date: 2024-07-03

Last Posted Date: 2025-05-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 98

Registration Number: NCT06483334

Locations: 🇮🇱
Sheba Medical Center-ONCOLOGY ( Site 4503), Ramat Gan, Israel
🇺🇸
University of California San Francisco HDFCCC ( Site 4044), San Francisco, California, United States
🇺🇸
Indiana University Melvin and Bren Simon Cancer Center ( Site 4011), Indianapolis, Indiana, United States

and more 20 locations

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

Phase 2

Active, not recruiting

Conditions: Non-alcoholic Fatty Liver Disease
Liver Disease
Metabolic Dysfunction-Associated Steatotic Liver Disease
Nonalcoholic Fatty Liver Disease

Interventions: Drug: Efinopegdutide

First Posted Date: 2024-07-01

Last Posted Date: 2024-11-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 129

Registration Number: NCT06482112

Locations: 🇺🇸
Gastroenterology and Liver Institute ( Site 0263), Escondido, California, United States
🇺🇸
Excel Medical Clinical Trials ( Site 0268), Boca Raton, Florida, United States
🇺🇸
Neoclinical Research ( Site 0275), Hialeah, Florida, United States

and more 36 locations

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Phase 1

Recruiting

Conditions: Gastroesophageal Junction
Gastroesophageal Adenocarcinoma
Esophageal Neoplasms
Esophageal Cancer

Interventions: Biological: Pembrolizumab
Drug: Capecitabine
Biological: Sacituzumab Tirumotecan (sac-TMT)
Drug: Leucovorin
Drug: Levoleucovorin
Drug: 5-FU

First Posted Date: 2024-06-24

Last Posted Date: 2025-05-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 130

Registration Number: NCT06469944

Locations: 🇨🇳
The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Site 5501), Fuzhou, Fujian, China
🇧🇷
Liga Norte Riograndense Contra o Câncer ( Site 6303), Natal., Rio Grande Do Norte, Brazil
🇧🇷
Hospital Nossa Senhora da Conceição ( Site 6301), Porto Alegre, Rio Grande Do Sul, Brazil

and more 34 locations

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Phase 2

Recruiting

Conditions: NAFLD
Metabolic Dysfunction-associated Steatotic Liver Disease
Non-alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis
Metabolic Dysfunction-associated Steatohepatitis

Interventions: Combination Product: Efinopegdutide
Combination Product: Placebo

First Posted Date: 2024-06-18

Last Posted Date: 2025-05-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 80

Registration Number: NCT06465186

Locations: 🇺🇸
The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 0149), Chandler, Arizona, United States
🇺🇸
Arizona Clinical Trials ( Site 0158), Flagstaff, Arizona, United States
🇺🇸
The Institute for Liver Health II dba Arizona Liver Health - Peoria ( Site 0120), Peoria, Arizona, United States

and more 59 locations

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

Phase 1

Recruiting

Conditions: Neoplasm Metastasis

Interventions: Biological: MK-6837
Biological: Pembrolizumab

First Posted Date: 2024-06-14

Last Posted Date: 2025-05-02

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 100

Registration Number: NCT06460961

Locations: 🇺🇸
Atlantic Health System Morristown Medical Center ( Site 4001), Morristown, New Jersey, United States
🇺🇸
Providence Portland Medical Center ( Site 4002), Portland, Oregon, United States
🇦🇺
Westmead Hospital ( Site 1002), Westmead, New South Wales, Australia

and more 3 locations

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Phase 3

Recruiting

Conditions: Cervical Cancer

Interventions: Biological: Sacituzumab Tirumotecan
Drug: Pemetrexed
Biological: Tisotumab Vedotin
Drug: Topotecan
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Irinotecan

First Posted Date: 2024-06-14

Last Posted Date: 2025-05-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 686

Registration Number: NCT06459180

Locations: 🇨🇳
Wuhan Union Hospital ( Site 5020), Wuhan, Hubei, China
🇨🇳
Hubei Cancer Hospital-Hubei Cancer Hospital ( Site 5019), Wuhan, Hubei, China
🇫🇷
Groupe Hospitalier Diaconesses Croix Saint Simon ( Site 1506), Paris, France

and more 207 locations

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Phase 3

Recruiting

Conditions: Essential Thrombocythemia

Interventions: Drug: Bomedemstat
Drug: Hydroxyurea
Drug: Hydroxyurea placebo
Drug: Bomedemstat placebo

First Posted Date: 2024-06-13

Last Posted Date: 2025-05-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 300

Registration Number: NCT06456346

Locations: 🇦🇷
Hospital Italiano de Buenos Aires ( Site 0102), ABB, Caba, Argentina
🇦🇷
C.I.C.E. 9 de Julio ( Site 0104), San Miguel de Tucumán, Tucuman, Argentina
🇦🇷
Clínica de Nefrología, Urología y Enfermedades Cardiovasculares ( Site 0105), Santa Fe, Argentina

and more 113 locations

A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Ezetimibe
Drug: Bempedoic Acid
Drug: Enlicitide Decanoate
Other: Placebo for Ezetimibe
Other: Placebo for Enlicitide Decanoate
Other: Placebo for Bempedoic Acid

First Posted Date: 2024-06-10

Last Posted Date: 2025-05-23

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 301

Registration Number: NCT06450366

Locations: 🇺🇸
Clinical Trials Research ( Site 1509), Lincoln, California, United States
🇺🇸
Velocity Clinical Research Rockville ( Site 1503), Rockville, Maryland, United States
🇺🇸
Rainier Clinical Research Center ( Site 1502), Renton, Washington, United States

and more 32 locations

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Phase 1

Recruiting

Conditions: Gastroesophageal Adenocarcinoma
Esophageal Neoplasms
Gastroesophageal Junction
Esophageal Cancer

Interventions: Biological: Ramucirumab
Drug: Paclitaxel
Biological: Sacituzumab Tirumotecan
Drug: Rescue Medications

First Posted Date: 2024-06-06

Last Posted Date: 2025-06-04

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 90

Registration Number: NCT06445972

Locations: 🇺🇸
Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 8907), New York, New York, United States
🇨🇱
Clínica Puerto Montt ( Site 8409), Puerto Montt., Los Lagos, Chile
🇨🇳
The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Site 7501), Fuzhou, Fujian, China

and more 35 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy